Inluriyo (Imlunestrant) in ER+/HER2– ESR1-Mutated Breast Cancer: Clinical Impact from EMBER-3

Scheduled for:Feb 27, 2026 7:00 PM EDT

Call Duration:30 minutes

Desired Expert

A medical oncologist specializing in breast cancer, with expertise in endocrine resistance mechanisms, ESR1 mutation testing, and the clinical integration of next-generation SERDs. The expert should be involved in clinical research or practice settings treating advanced hormone receptor-positive breast cancer, with familiarity in optimizing treatment sequencing post-CDK4/6 inhibition and aromatase inhibitor therapy.

Interview Goal

This interview aims to explore the clinical implications of the U.S. FDA approval of Inluriyo (imlunestrant) for adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC), based on findings from the Phase 3 EMBER-3 trial. The discussion will assess the magnitude of benefit in progression-free survival, its role as an oral selective estrogen receptor antagonist and degrader (SERD), safety and tolerability outcomes, and how Inluriyo may reshape endocrine therapy sequencing for ESR1-mutated disease.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.